Last reviewed · How we verify

NCT04029142

Screening for Hemoglobinopathies in Pregnant Women

Completed Last updated 4 March 2024
What this trial tests

trial testing Review of routine lab data in Hemoglobinopathies in 1,785 participants. Completed in 30 September 2019.

Timeline
3 July 2019
Primary endpoint
30 September 2019
30 September 2019

Quick facts

Lead sponsorUniversity Hospital, Basel, Switzerland
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,785
Start date3 July 2019
Primary completion30 September 2019
Estimated completion30 September 2019
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Basel, Switzerland

Who can join

Eligibility, female only, with Hemoglobinopathies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective monocentric study project is to identify hemoglobinopathies in pregnant women in order to optimize antenatal care and to investigate the prevalence of hemoglobinopathies in pregnant women in Switzerland.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cohort profile: targeted antenatal screening for haemoglobinopathies in Basel.
    Amstad Bencaiova G, Geissler F, Hoesli I. · · 2020 · cited 1× · PMID 32699163 · DOI 10.1136/bmjopen-2019-035735

Verify or expand the search:

Other recruiting trials for Hemoglobinopathies

Currently open trials in the same condition.

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04029142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing